ACE2 and COVID-19: This antibody, derived from B cells specific for the SARS-CoV-2 S glycoprotein, was isolated from a COVID-19-infected individual and targets the receptor-binding domain (RBD; residues 319–591), effectively blocking the RBD-ACE2 interaction [57].